Abbott Chairman of the Board and CEO Robert B. Ford delivers a keynote address at CES 2022 at The Venetian Las Vegas on January 6, 2022 in Las Vegas, Nevada. Ethan Miller | Getty Images Abbott Laboratories announced Monday it received approval from the U.S. Food and Drug Administration for two new continuous glucose monitoring…
Read More “FDA approves two new Abbott over-the-counter continuous glucose monitors” »
Exterior view of the Pfizer headquarters building in New York City on Jan. 29, 2023. Kena Betancur | Corbis News | Getty Images Pfizer on Wednesday said it has launched a new multiyear program to reduce costs as it works to rebound from the rapid decline of its Covid business. The announcement is in addition…
Read More “Pfizer aims to save $1.5 billion by 2027 in first wave of new cost cuts” »
Amgen‘s stock rose more than 12% on Friday after the drugmaker teased positive initial data on its experimental weight loss injection. That fueled investor concerns about new competition in the rapidly growing weight loss drug industry, sending shares of the current obesity players, Novo Nordisk and Eli Lilly, lower on Friday. Eli Lilly shares dropped…
The eponymous sign outside Epic headquarters in Verona, Wisconsin. Source: Yiem via Wikipedia CC Epic Systems, the largest provider of software for managing medical records, says a venture-backed startup called Particle Health is using patient data in unauthorized and unethical ways that have nothing to do with treatment. Epic told customers in a notice on…
The Food and Drug Administration on Tuesday approved a drug from Merck designed to treat a progressive and life-threatening lung condition in a win for both the drugmaker and for patients suffering from the rare disease. The agency greenlighted the therapy, which will be marketed as Winrevair, for adults with pulmonary arterial hypertension. The decision…
Read More “FDA approves Merck’s drug for rare, deadly lung condition” »
In this photo illustration the UnitedHealth Group logo displayed on a smartphone screen. Sheldon Cooper | Sopa Images | Lightrocket | Getty Images UnitedHealth Group on Thursday said it expects to restore Change Healthcare’s systems by mid-March, offering a potential resolution to the ransomware attack that has disrupted crucial operations across the U.S. health-care system….
Read More “UnitedHealth working to restore Change Healthcare systems by mid-March, company says” »
It’s been hard to keep up. That’s the story of the big stock winners this year. They just keep winning and winning and winning. For analysts on Wall Street and here at the Club, it seems like some of these names are smashing through our six-to-nine-month price targets every few weeks. To that end, we’re…
Read More “In this fast-paced bull market, we’re increasing our Club price targets on 4 stocks” »
A Humana Inc. office building in Louisville, Kentucky, Feb. 3, 2019. Bloomberg | Bloomberg | Getty Images Shares of Humana plummeted Thursday after the health insurer issued dismal full-year earnings guidance, citing soaring medical costs that are dogging the broader insurance industry. Those expenses have spiked as an increasing number of older adults return to…
Read More “Humana stock plunges on dismal 2024 forecast, as insurers face soaring medical costs” »
WASHINGTON — Amid tensions in the Middle East, Secretary of Defense Lloyd Austin was hospitalized, including spending four days in the intensive care unit, according to two senior administration officials. The Pentagon did not inform senior officials in the White House’s National Security Council of Austin’s hospitalization until Thursday — three days after he arrived…
George Frey | Bloomberg | Getty Images Weight loss drugs exploded into the public eye this year, and 2024 will bring more change to the evolving market. The drugs skyrocketed in popularity in 2023 as they helped patients shed significant weight, despite hefty price tags, mixed insurance coverage and a handful of unpleasant side effects. …
Read More “The weight loss drug boom isn’t over yet — here’s what to expect in the year ahead” »
